2015-001544-11
Study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Philippines
GlaxoSmithKline Biologicals·EU Clinical Trials Register
Study focus
- Disease/Condition
- Healthy volunteers
Sponsor & location
- Primary sponsor
- GlaxoSmithKline Biologicals
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Primary outcome
Anti-RV IgA antibody seroconversion, when administered concomitantly with the second and third routine EPI immunization
ICD-10 classifications
Healthy person accompanying sick personRoutine general health check-up of armed forcesRoutine general health check-up of sports teamsRoutine general health check-up of inhabitants of institutions
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2015-001544-11
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2015-001544-11 through Pure Global AI's free database. This phase not specified trial is sponsored by GlaxoSmithKline Biologicals and is currently status unknown. The study focuses on Healthy volunteers.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.